Actively Recruiting
Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose
Led by SunWay Biotech Co., LTD. · Updated on 2025-08-28
80
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
CONDITIONS
Official Title
Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or non-pregnant women over 20 years old who are mentally capable of communication
- Body mass index (BMI) between 18 and 35
- Mean corpuscular volume (MCV) in blood routine examination not less than 70 fL
- Blood sugar meeting any of these: fasting blood sugar between 100 and 125 mg/dL without need for hypoglycemic drugs, or glycated hemoglobin between 5.7% and 6.4% without need for hypoglycemic drugs, or diabetic patients not taking hypoglycemic drugs in the past month and unwilling to take medicine
- No serious diseases such as cancer, heart failure, myocardial infarction, liver cirrhosis, moderate to severe liver or kidney dysfunction, or stroke
- No use of hypoglycemic drugs during the trial; withdrawal required if hypoglycemic drugs become necessary
- Maintains regular daily routine and eating habits without deliberate changes during the trial
You will not qualify if you...
- Systolic blood pressure equal to or above 200 mmHg or diastolic blood pressure equal to or above 140 mmHg
- Moderate or severe liver and kidney dysfunction, including elevated liver enzymes more than three times the normal limit or diagnosed liver cirrhosis, or low glomerular filtration rate (eGFR 30 ml/min/1.73m2 or less)
- Pregnant or lactating women
- Diabetic patients currently taking hypoglycemic drugs or insulin injections
- Use of traditional Chinese medicine mainly containing red yeast rice
- Surgery within the past month
- Serious diseases affecting heart, liver, kidney, or blood system, mentally ill patients not meeting inclusion criteria, or inability to follow test requirements resulting in incomplete or unreliable data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tri-Service General Hospital, National Defense Medical Center, Taipei city,
Taipei, Taiwan, 114202
Actively Recruiting
Research Team
S
Sean Lin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here